Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional ...

Avidity Biosciences, Inc. ( NASDAQ: RNA) Discusses on Redefining the Treatment of Duchenne Muscular Dystrophy Conference Call September 10, 2025 8:00 AM EDT ...

Get the latest on Avidity Biosciences' late-stage RNA drug pipeline, upcoming FDA filings, and market opportunities for rare muscle diseases.

Drs. Amy Proal and David Putrino will present the proposed study design for the consideration of RECOVER-TLC at the Second Annual RECOVER-TLC Workshop being held September 9-10, 2025 in Bethesda, ...

Summary: A new study suggests that autism may be linked to the rapid evolution of brain cell types unique to humans.

Manufacturing excellence positions Seattle site as premier destination for mammalian and microbial biologic production in thriving Pacific Northwest life sciences hubSEATTLE--(BUSINESS WIRE)--AGC ...

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapiesPatient dosing ...

Dana Orange’s research may help predict flares, provide precise drug targets, and enable interventions that block symptoms ...

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Patient dosing expected to commence in H2 2025; Topline data anticipated ...